Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel
19 Dicembre 2024 - 6:00PM
UK Regulatory
Change in Orion Group Executive Management Board as of 1 June 2025
– Mikko Kemppainen appointed General Counsel
ORION CORPORATION
STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS
19 DECEMBER 2024 at 19.00 EET
Change in Orion Group Executive Management Board as of 1 June 2025
– Mikko Kemppainen appointed General Counsel
Olli Huotari, Senior Vice President responsible
for Corporate Functions organization of the Orion Group and
Secretary to the Board of Directors of Orion Corporation, and a
member of the Executive Management Board of the Orion Group
informed earlier of his decision to leave Orion on 31 May
2025. Mikko Kemppainen has been appointed as
General Counsel and Secretary to the Board of Directors of Orion
Corporation, and a member of the Executive Management Board of the
Orion Group as of 1 June 2025.
The appointed General Counsel Mikko Kemppainen will be responsible
for the following of Olli Huotari’s responsibility areas:
Compliance, Intellectual Property Rights, Legal Affairs, and Public
Affairs. Other responsibility areas of Huotari will be transferred
to other members of the Executive Management Board of the Orion
Group as of June 1, 2025.
Mikko Kemppainen holds a Master of Laws (Trained at the Bench)
degree. He joined Orion as a Legal Counsel in 2006 and has been the
Head of Legal Affairs at Orion Corporation since 2007. Prior to
joining Orion, Kemppainen worked as Associate and Senior Associate
at Hannes Snellman Attorneys Ltd during 2000−2006.
President and CEO Liisa
Hurme says:
“I would like to sincerely thank Olli Huotari for his long and
distinguished career at Orion in various roles. We have worked
closely together for years, and he has been the most reliable and
pleasant colleague in every situation.
Liisa Hurme continues:
“I warmly welcome Mikko Kemppainen to the Orion Executive
Management Board to implement our growth strategy together. I am
glad that the best candidate for the position was found within the
company. I believe that Mikko’s long experience with Orion and from
the pharmaceutical industry will be valuable in his new position. I
look forward to working with him in the executive management
board.”
“I’m honored by this appointment and excited about the opportunity
to join Orion’s Executive Management Board. Orion is a fine company
and I’m looking forward to continue the work for its growth and
success in my new role”, says Mikko Kemppainen.
Olli Huotari says:
“I have always appreciated and been very grateful for all the
positions and career Orion has offered to me. Orion is an
excellent company with great people. I wish the company, its
stakeholders, and especially the Orionees all the best and success
also in the future!“
ANNEX: CV of Mikko Kemppainen
Mikko Kemppainen
Born 1972
Finnish citizen
Education:
Master of Laws, University of Lapland, Finland, 1998
Career:
Paul Henriksson Attorneys at Law
Assisting lawyer, 1998−1999
District Court of Tornio, Finland
Bench Training, 1999−2000
District Court Judge, 2000
Hannes Snellman Attorneys
Ltd.
Associate, Senior Associate 2000−2006
Orion Corporation
Legal Counsel, 2006−2007
Head of Legal Affairs, 2007−
Orion Corporation
Liisa Hurme
President and CEO |
Terhi Ormio
Vice President, Communications
|
Contact person:
Liisa Hurme, President and CEO
Tel. + 358 50 966 2874
Contact person for the media:
Terhi Ormio, Vice President, Communications
Tel. +358 50 966 4646
terhi.ormio@orion.fi
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a
builder of well-being for over a hundred years. We develop,
manufacture and market human and veterinary pharmaceuticals and
active pharmaceutical ingredients. Orion has an extensive portfolio
of proprietary and generic medicines and consumer health products.
The core therapy areas of our pharmaceutical R&D are oncology
and pain. Proprietary products developed by Orion are used to treat
cancer, neurological diseases and respiratory diseases, among
others. Orion's net sales in 2023 amounted to EUR 1,190 million and
the company had about 3,600 employees at the end of the year.
Orion's A and B shares are listed on Nasdaq Helsinki.
Grafico Azioni Orion (BIT:1ORNBV)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Orion (BIT:1ORNBV)
Storico
Da Gen 2024 a Gen 2025
